StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Investment analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

Several other research analysts have also recently issued reports on EKSO. HC Wainwright cut their target price on shares of Ekso Bionics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Lake Street Capital cut their target price on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th.

Ekso Bionics Trading Down 11.5%

EKSO stock opened at $0.40 on Wednesday. The company has a market capitalization of $11.62 million, a PE ratio of -0.62 and a beta of 1.09. Ekso Bionics has a one year low of $0.34 and a one year high of $1.53. The company’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to analysts’ expectations of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. As a group, analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC boosted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,042,382 shares of the company’s stock after acquiring an additional 316,733 shares during the period. Armistice Capital LLC owned 7.03% of Ekso Bionics worth $823,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.